• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

    2/27/24 2:32:26 PM ET
    $HIMS
    $JANX
    $NERV
    $NRXP
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HIMS alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.

    The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40.

    Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 5% Dividend Yields

     

    Leading and Lagging Sectors

     

    Utilities shares rose by 1.2% on Tuesday.

    In trading on Tuesday, energy shares fell by 0.4%.

     

    Top Headline

     

    The J.M. Smucker Company (NYSE:SJM) posted better-than-expected earnings for its fourth quarter on Tuesday.

    The company reported third-quarter adjusted earnings per share of $2.48, beating the analyst consensus of $2.27. J.M. Smucker registered quarterly revenues of $2.229 billion, marginally beating the consensus estimate of $2.220 billion.

     

    Equities Trading UP

     

    Janux Therapeutics, Inc. (NASDAQ:JANX) shares shot up 191% to $44.00 after the company announced updated clinical data for both of its clinical programs.

    Shares of Hims & Hers Health, Inc. (NYSE:HIMS) got a boost, surging 32% to $13.50 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.

    Viking Therapeutics, Inc. (NASDAQ:VKTX) shares were also up, gaining 94% to $74.79 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.

     

    Equities Trading DOWN

     

    Minerva Neurosciences, Inc. (NASDAQ:NERV) shares dropped 57% to $2.95 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

    Shares of Thoughtworks Holding, Inc. (NASDAQ:TWKS) were down 31% to $3.1785 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was down, falling 33% to $0.2851 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.

    Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

     

    Commodities

     

    In commodity news, oil traded up 1.6% to $78.81 while gold traded up 0.1% at $2,041.60.

    Silver traded fell 0.3% to $22.46 on Tuesday while copper rose 0.4% to $3.85.

     

    Euro zone

     

    European shares closed mixed today. The eurozone’s STOXX 600 fell 0.18%, London’s FTSE 100 fell 0.02% while Spain’s IBEX 35 Index fell 0.24% The German DAX gained 0.76% French CAC 40 rose 0.23% while Italy’s FTSE MIB Index rose 0.46%.

    Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February's level of 29.6.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Tuesday, with Japan’s Nikkei 225 gaining 0.01%, Hong Kong’s Hang Seng Index climbing 0.94%, China’s Shanghai Composite Index surging 1.29% and India’s S&P BSE Sensex gaining 0.4%.

    Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.

     

    Economics

     

    U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.

    The FHFA house price index rose 0.1% in December following a 0.4% increase in November.

    The S&P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.

    The Dallas Fed general business activity index for Texas’ service sector rose to -3.9 in February from -9.3 in the previous month

    Now Read This: Roku, Crocs And 2 Other Stocks Insiders Are Selling

     

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS
    $JANX
    $NERV
    $NRXP

    CompanyDatePrice TargetRatingAnalyst
    The J.M. Smucker Company
    $SJM
    1/16/2026$105.00Overweight → Equal-Weight
    Morgan Stanley
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    Janux Therapeutics Inc.
    $JANX
    11/18/2025Peer Perform
    Wolfe Research
    Viking Therapeutics Inc.
    $VKTX
    10/29/2025$106.00Buy
    Canaccord Genuity
    Hims & Hers Health Inc.
    $HIMS
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    Janux Therapeutics Inc.
    $JANX
    9/17/2025$47.00Overweight
    Barclays
    The J.M. Smucker Company
    $SJM
    9/12/2025Buy → Hold
    Argus
    More analyst ratings

    $HIMS
    $JANX
    $NERV
    $NRXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Amin Tarang bought $100,894 worth of shares (1,050 units at $96.09), increasing direct ownership by 38% to 3,825 units (SEC Form 4)

    4 - J M SMUCKER Co (0000091419) (Issuer)

    6/12/25 5:42:45 PM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/8/25 7:05:30 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/2/25 6:29:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $NERV
    $NRXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The J.M. Smucker Co. Announces Senior Leadership Updates to Drive Continued Growth and Execution

    ORRVILLE, Ohio, Feb. 10, 2026 /PRNewswire/ -- The J.M. Smucker Co. today announced a series of leadership updates that are designed to advance the Company's continued execution of its long-term growth strategy and further the momentum of its portfolio of leading brands, while enhancing profitability and earnings. Tucker Marshall, who has served as Chief Financial Officer, has been promoted to the new role of Chief Financial Officer | Executive Vice President, Frozen Handheld and Spreads and Sweet Baked Snacks. In addition to financial reporting, internal audit, tax and treasury, financial planning and analysis, investor relations, and corporate development, Marshall's oversight has expanded

    2/10/26 9:00:00 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

    San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you. Purpose and Scope This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss

    2/5/26 8:51:30 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    The J.M. Smucker Co. Announces the Election of Katie Williams to Chief Marketing Officer

    ORRVILLE, Ohio, Feb. 5, 2026 /PRNewswire/ -- The J.M. Smucker Co. today announced the election of Katie Williams to the role of Chief Marketing Officer, reporting to Mark Smucker, Chief Executive Officer and Chair of the Board, effective March 9.  "We are thrilled to welcome Katie to the Company. She brings deep expertise and a strong track record of building leading brands," said Smucker. "I am confident she will help to advance our portfolio of leading brands forward and elevate our world-class marketing capabilities."   Williams brings more than 20 years of experience build

    2/5/26 9:00:00 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    $HIMS
    $JANX
    $NERV
    $NRXP
    SEC Filings

    View All

    The J.M. Smucker Company filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - J M SMUCKER Co (0000091419) (Filer)

    2/10/26 8:59:52 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    2/9/26 6:43:50 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

    SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

    2/6/26 4:23:27 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $NERV
    $NRXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HIMS
    $JANX
    $NERV
    $NRXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:01:40 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Go William

    3 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:00:24 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 5,262 shares at a strike of $5.01 and sold $139,108 worth of shares (5,262 units at $26.44) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    2/4/26 4:13:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    J.M. Smucker downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded J.M. Smucker from Overweight to Equal-Weight and set a new price target of $105.00

    1/16/26 8:30:16 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $JANX
    $NERV
    $NRXP
    Leadership Updates

    Live Leadership Updates

    View All

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $NERV
    $NRXP
    Financials

    Live finance-specific insights

    View All

    The J.M. Smucker Co. Announces Senior Leadership Updates to Drive Continued Growth and Execution

    ORRVILLE, Ohio, Feb. 10, 2026 /PRNewswire/ -- The J.M. Smucker Co. today announced a series of leadership updates that are designed to advance the Company's continued execution of its long-term growth strategy and further the momentum of its portfolio of leading brands, while enhancing profitability and earnings. Tucker Marshall, who has served as Chief Financial Officer, has been promoted to the new role of Chief Financial Officer | Executive Vice President, Frozen Handheld and Spreads and Sweet Baked Snacks. In addition to financial reporting, internal audit, tax and treasury, financial planning and analysis, investor relations, and corporate development, Marshall's oversight has expanded

    2/10/26 9:00:00 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

    Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

    2/4/26 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $JANX
    $NERV
    $NRXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Thoughtworks Holding Inc.

    SC 13D/A - Thoughtworks Holding, Inc. (0001866550) (Subject)

    11/15/24 4:15:12 PM ET
    $TWKS
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Thoughtworks Holding Inc.

    SC 13D/A - Thoughtworks Holding, Inc. (0001866550) (Subject)

    11/15/24 4:05:56 PM ET
    $TWKS
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care